Recent Alerts

endoscopic stapedotomy is associated with similar hearing improvements as microscopic stapedotomy but lower rates of postoperative pain and dysgeusia (Otolaryngol Head Neck Surg 2025 Apr)

View in Otosclerosis

high-dose corticosteroid therapy is similarly effective at improving hearing compared to a lower-dose regimen but is associated with a higher rate of adverse effects in adults with sudden sensorineural hearing loss (NEJM Evid 2024 Jan)

View in Sudden Sensorineural Hearing Loss

fitusiran (Qfitlia) is FDA approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients ≥ 12 years old with hemophilia B with or without factor IX inhibitors (FDA Press Release 2025 Mar 28)

View in Prophylaxis in Patients With Hemophilia B

fitusiran (Qfitlia) is FDA approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients ≥ 12 years old with hemophilia A with or without factor VIII inhibitors (FDA Press Release 2025 Mar 28)

View in Prophylaxis in Patients With Hemophilia A

Durvalumab (Imfinzi) receives expanded FDA approval in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by monotherapy as adjuvant treatment after radical cystectomy for the treatment of adults with muscle invasive bladder cancer (FDA Press Release 2025 Mar 31)

View in Management of Nonmetastatic Muscle Invasive Bladder Cancer

nedosiran (Rivfloza) receives expanded FDA approval to lower urinary oxalate levels in patients ≥ 2 years old with primary hyperoxaluria type 1 and relatively preserved kidney function (estimated glomerular filtration rate ≥ 30 mL/minute/1.73 m2) (FDA Product Information 2025 Mar)

View in Hyperoxaluria

diazoxide (Vykat XR) is FDA approved for the treatment of hyperphagia in patients ≥ 4 years old with Prader-Willi syndrome (FDA Product Information 2025 Mar)

View in Prader-Willi Syndrome

FDA grants marketing authorization for a nonprescription home-based diagnostic test for chlamydia, gonorrhea, and trichomoniasis (Visby Medical Women’s Sexual Health Test) intended for use in female patients with or without symptoms (FDA Press Release 2025 Mar 28)

View in Chlamydia Genital Infection

gepotidacin (Blujepa) is FDA approved for the treatment of uncomplicated urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis in female patients ≥ 12 years old weighing ≥ 40 kg (FDA DailyMed 2025 Mar 25)

View in Uncomplicated Urinary Tract Infection in Female Adults

National Comprehensive Cancer Network (NCCN) recommendations on management of appendiceal neuroendocrine tumors and carcinomas (NCCN 2025 Mar)

View in Appendiceal Cancer